People's Justice

Case guide

The federal Zantac ruling: what was its scope?

The federal court rejected expert proof for five cancer types in 2022. A later order describes that ruling.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202613 sources

This may apply to you if

  • Preparation suggestions only; no cancer list, use-duration threshold or current firm acceptance rule is verified.
  • Describe the product, dates and diagnosis you want checked.
  • Ask a lawyer what evidence and court route apply to your own situation.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Robin L. Rosenberg · United States District Court, Southern District of Florida · District judge signing order 81

Finding: The February 2023 order distinguishes five designated cancers from other injuries and recalls prior federal expert-evidence rulings. Its scope does not decide every state claim.

Federal court: February 14, 2023 Zantac order 81 (opens in a new tab) · Feb 14, 2023 · Checked Oct 4, 2026

The evidence and its limits

Yonsei University College of Medicine, first-author affiliation · JAMA Network Open · 2023

Ranitidine Use and Incident Cancer in a Multinational Cohort

Design:
Cohort
Participants:
1,183,999 eligible people across eleven analytical databases: 909,168 new ranitidine users and 274,831 other H2-blocker users. Primary meta-analysis used four databases meeting stricter balance criteria.
Finding:
The primary and broader comparisons did not show a statistically significant overall cancer increase relative to other H2 blockers.
Main limitation
Prescription or dispensing data do not capture all actual or nonprescription use; individual impurity and dietary exposure were not measured. Follow-up may miss long-latency effects and rare or small differences. The paper reports distinct primary, broader and calibrated estimates; no pooled number is presented as one universal eleven-database result. No individual cause or universal safety finding.

Read the source: Ranitidine Use and Incident Cancer in a Multinational Cohort (opens in a new tab) · Checked Oct 4, 2026

Tainan Municipal Hospital, first-author affiliation · International Journal of Environmental Research and Public Health · 2022

Pharmacoepidemiological research on NDMA-contaminated ranitidine use and long-term cancer risk

Design:
Cohort
Participants:
55,110 ranitidine users and 55,110 matched untreated people; additional drug-comparison analyses are separate.
Finding:
Several cancer rates were higher in the ranitidine group compared with untreated controls.
Main limitation
Observational matching cannot balance unknown factors. Personal impurity, smoking, alcohol and complete actual use were unavailable. Authors declared no conflicts and no funder role; that is not a review or endorsement of PJ.

Read the source: Pharmacoepidemiological research on NDMA-contaminated ranitidine use and long-term cancer risk (opens in a new tab) · Checked Oct 4, 2026

The short answer

What does the federal case group number mean?
MDL means shared federal court work. This group is MDL 2924. It does not mean every user has one injury or the same outcome. [13]
What did the February 2023 order say about 2022?
The order says the court rejected general-cause expert proof for five cancers in December 2022. The brands won the related request to end those claims. [13]
What happened to other cancer claims in that order?
The court set a separate process for expert proof of other cancers. Those claims did not win just because the type was outside the five groups. [13]
Was FDA’s withdrawal the same as courtroom proof?
No. FDA asked makers to pull the older drug from the market. A safety step and proof a court accepts answer different questions. [4]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

The federal court rejected expert proof for five cancer types in 2022. A later order describes that ruling. It does not decide every state case or give your own filing limit.

What does the federal case group number mean?

MDL means shared federal court work. This group is MDL 2924. It does not mean every user has one injury or the same outcome.

The Southern District of Florida’s order identifies Judge Robin L. Rosenberg. A group number organizes related proceedings; it is not proof that a particular person filed a case or receives a payment.

What did the February 2023 order say about 2022?

The order says the court rejected general-cause expert proof for five cancers in December 2022. The brands won the related request to end those claims.

The list was bladder, esophageal, gastric, liver and pancreatic. The later order reports the earlier ruling; it should not be mistaken for a fresh 2026 decision or a verdict against every drug user.

What happened to other cancer claims in that order?

The court set a separate process for expert proof of other cancers. Those claims did not win just because the type was outside the five groups.

The document explains requirements for certain brand cases and distinguishes other parties. Its historical case-management dates do not set a personal national deadline for someone reading now.

Was FDA’s withdrawal the same as courtroom proof?

No. FDA asked makers to remove the older drug. A safety action and proof accepted in court answer different questions.

A product concern does not identify the dose in a person’s tablets. The court order concerns scientific proof and procedural requirements, not a personal medical finding that every former user developed drug-caused cancer.

Do study findings settle the legal or personal issue?

No. The 2023 comparison found no clear overall rise; the 2022 cohort found higher rates for several cancers. Both have limits.

Different comparison groups and missing exposure or health data matter. A court assesses the evidence under its legal rules. Neither a study result nor the date on a paper supplies an individual award.

Did the federal ruling decide all state cases too?

No. Read the state order on its own. Delaware’s April 2026 order covers claims filed on or before December 1, 2025.

The Delaware opinion also addresses later-filed evidence without guaranteeing a route or outcome. Give a lawyer your case papers so they can assess the court and orders that apply.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  2. Southern District of New York: time limitsSouthern District of New York: time limits · court
  3. 45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
  4. FDA: April2020 ranitidine withdrawal requestFDA: April2020 ranitidine withdrawal request · regulator
  5. FDA: reformulated ranitidine approvalFDA: reformulated ranitidine approval · regulator
  6. You: original multinational ranitidine cancer cohortYou: original multinational ranitidine cancer cohort · study
  7. Wang: original Taiwan ranitidine cohortWang: original Taiwan ranitidine cohort · study
  8. Jones: April14,2026 Delaware Zantac orderJones: April14,2026 Delaware Zantac order · court
  9. Jones: January29,2026 Delaware time-limit rulingJones: January29,2026 Delaware time-limit ruling · court
  10. GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability. GSK also agreed to pay $70 million to resolve the Valisure qui tam complaint. Verified from GSK's own press statement.us.gsk.com · Oct 9, 2024
  11. Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month). Sanofi denied liability; 70,000+ suits then remained, mostly in Delaware.insurancejournal.com · Apr 23, 2024 · study
  12. MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims. Verified from the court order itself.gsk.com · Dec 6, 2022 · court
  13. Federal court: February 14, 2023 Zantac order 81

Checked against 10 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026